

Endocyte, Inc. Logo

## Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

June 22, 2018

### Presentations highlight Endocyte's alpha and beta-emitting radioligand therapies

WEST LAFAYETTE, Ind., June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple presentations related to Endocyte's PSMA-617 radioligand therapy will be presented at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) being held from June 23<sup>rd</sup> - 26<sup>th</sup>, 2018 in Philadelphia, PA.

"We are pleased that our leading radio-ligand therapy (RLT) platform, which includes <sup>177</sup>Lu-PSMA-617, and <sup>225</sup>Ac-PSMA-617, will be prominently featured throughout the program at SNMMI," said Mike Sherman, president and CEO of Endocyte. "<sup>225</sup>Ac-PSMA-617 is an alpha emitting RLT with the potential to expand the application of PSMA-617, and has been examined in over 100 patients with compelling response rates to date. We intend to provide more details on our strategy to develop <sup>225</sup>Ac-PSMA-617 in the second half of 2018, including leveraging existing clinical data sets to accelerate development."

#### Key Presentations and Symposia at SNMMI:

Endocyte's chief medical officer, Dr. Alison Armour, will provide an overview of <sup>177</sup>Lu-PSMA-617 development during the Emerging Technology Session.

Title: Updates on <sup>177</sup>Lu-PSMA-617  
When: Monday, June 25, 2018 at 3:00 p.m. – 5:00 p.m. EDT  
Session Title: CMIIT Emerging Technologies – A look into the Future of Molecular Imaging and Therapy  
Location: 112AB (Pennsylvania Convention Center)

Professor Mike Sathegke from the University of Pretoria will present data from an investigator-sponsored trial of Endocyte's alpha-emitting radioligand therapy <sup>225</sup>Ac-PSMA-617.

Abstract #: 530  
Title: Targeted Alpha Therapy of mCRPC with <sup>225</sup>Actinium-PSMA617: Dosimetry, toxicity and duration of tumor-control  
When: Tuesday, June 26, 2018 at 10:00 a.m. – 11:30 a.m. EDT  
Session Title: SS62: Prostate: Therapy  
Location: 107AB (Pennsylvania Convention Center)

SNMMI will also host an all-day pre-meeting categorical seminar on PSMA-targeted radioligand therapies, including therapies using Endocyte's PSMA-617.

Title: CAT 3: PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT. The Power of Precision Oncology  
When: Saturday, June 23, 2018 from 7:30 a.m. – 3:00 p.m. EDT  
Location: 114 Michael A. Nutter Theatre (Pennsylvania Convention Center)

Several other discussions and posters covering PSMA-617 will be presented at the 2018 SNMMI. For a complete list of presentations, please visit the SNMMI Annual Meeting's web schedule at <https://webmobile.experientengage.com/~SNM181/#/>

#### Website Information

Endocyte routinely posts important information for investors on its website, [www.endocyte.com](http://www.endocyte.com), in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte's website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte's website is not incorporated by reference into, and is not a part of, this document.

#### About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, <sup>177</sup>Lu-PSMA-617, entering phase 3 for metastatic castration-resistant prostate cancer (mCRPC). Endocyte also expects to have an Investigational New Drug application submitted in the fourth quarter of 2018 for its adaptor-controlled CAR T-cell therapy which will be initially studied in osteosarcoma. For additional information, please visit Endocyte's website at [www.endocyte.com](http://www.endocyte.com).

#### Forward Looking Statements:

*Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's future development plans and presentation and status of clinical data. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company or independent investigators may experience delays in submission and review of regulatory applications, execution of clinical trials and/or the processing of clinical data. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

**Investor Contact:**

Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [michael@sternir.com](mailto:michael@sternir.com)

 [Primary Logo](#)

Source: Endocyte, Inc.